MedPath

Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure

Phase 3
Completed
Conditions
Pneumothorax
Registration Number
NCT00562302
Lead Sponsor
Angiotech Pharmaceuticals
Brief Summary

BS-1053 A Prospective Randomized Multi-Centered Safety and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures

Detailed Description

This is a multi-centered, randomized trial in patients receiving lung biopsies. Patients will be randomized to either receive or not receive a Bio-Seal Biopsy Track Plug after a lung biopsy per standard hospital protocol. This study is designed to demonstrate safety and efficacy of the Bio-Seal Biopsy Track Plug in reducing pneumothorax rates post lung biopsy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
339
Inclusion Criteria
  • The patient must meet all medical conditions for lung biopsy;
  • The patient must be at least 18 years of age;
  • The patient, or legal representative, must understand and provide written consent for the procedure;
  • The patient has a non-calcified, radiologically suspicious opacity or lung nodule, including a metastatic lung module, or mass of at least 1.0 cm in size; as determined by CT scan equipped with measurement software. Suspicious nodules observed by CT scan are defined as non-calcified masses with convex borders, not known to be stable. Suspicious nodules can also be defined as masses demonstrating opacity on chest x-ray that are suspicious by radiographic or clinical means and require biopsy.
Exclusion Criteria
  • Patients with radiological findings of bullous emphysema located in the area of the anticipated biopsy and biopsy needle track;
  • Patients who cannot tolerate mild sedation, possibly secondary to poor respiratory status;
  • Female patients who are pregnant. Note: patients of childbearing potential must have a serum or urine pregnancy test no more than one week prior to the biopsy procedure, and be instructed not to have unprotected sexual intercourse after the test until the biopsy procedure is completed.
  • Patients who are uncooperative or cannot follow instructions.
  • Patients who are currently enrolled in another IDE or IND clinical investigation that has not completed the required follow-up period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Incidence Rate of Treatment Success30 days

Treatment success was defined as the absence of a pneumothorax at each of the three follow-up time periods (0-60 minutes, 24 hours and 30 days).

Secondary Outcome Measures
NameTimeMethod
Incidence of Chest Tube Placement30 days

A chest tube is the definitive initial treatment of a pneumothorax.

Time to Ambulation30 days
Incidence of Hospital Admissions for Pneumothorax30 day
Incidence of Adverse Events Related to the Procedure and Device Effects30 Day

Anticipated, device-related adverse events that were defined in the original protocol.

Number of Participants With Additional Chest X-rays Needed30 day
Participants Discharged Beyond Hospital's Standard of Care30-day

Current standard of care for hospital discharge varies. Some institutions allow the patient to be discharged after a 3 hour wait. Others allow discharge after an x-ray indicates no pneumothorax. Since this study was randomized with control patients, the time to discharge beyond the hospital's standard of care was recorded to see if a trend for later discharge was apparent. This measure indicates the number of participants who were discharged later than their hospital's standard of care.

Incidence of Adverse Events30 days

Any treatment emergent adverse events (not considered device related by the investigators).

Trial Locations

Locations (18)

Scottsdale Medical Imaging

🇺🇸

Scottsdale, Arizona, United States

St. Josephs Radiology Limited

🇺🇸

Tuscon, Arizona, United States

UCLA School of Medicine

🇺🇸

Los Angeles, California, United States

Univerisity of California, San Diego

🇺🇸

San Diego, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Vascular and Interventional Radiology

🇺🇸

New Haven, Connecticut, United States

Morton Plant Mease Health Care

🇺🇸

Clearwater, Florida, United States

Florida Research Network

🇺🇸

Gainesville, Florida, United States

UMass Memorial Medical Center

🇺🇸

Worcester, Massachusetts, United States

St. Louis Medical Center

🇺🇸

St. Louis, Missouri, United States

Scroll for more (8 remaining)
Scottsdale Medical Imaging
🇺🇸Scottsdale, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.